Public-private partnerships instrumental in ensuring preventive healthcare, says Union Minister Nadda
Speaking to reporters in New Delhi on the sidelines of the Confederation Of Indian Industry (CII) Annual Business Summit-2025, Nadda emphasised the pivotal role of the private sector in driving India's healthcare, seeking the private sector to innovate in AI and tech-based innovations to enable mass screenings and telemedicine throughout the healthcare ecosystem.
'Health transformation doesn't happen overnight,' the Union Minister said stressing on the need to strategise to build systems that will serve future generations.
In his address to the CII summit, Nadda, emphasised the theme 'Building Trust- India First' and called for a unified national effort to strengthen healthcare systems aligned with India's 2047 development roadmap.
He underlining the government's unwavering commitment to healthcare reforms, innovation and accessibility, with a compelling vision for a healthier, more inclusive India, .
The Union Minister lauded the Confederation of Indian Industry (CII) for prioritising healthcare in its growth agenda and fostering dialogue among policymakers, industry leaders and key stakeholders.
'Such engagements are critical to nation-building and positioning India as a global leader in health innovation,' the minister said.
Further, Nadda called for a more humane, responsive and time-bound regulatory environment, especially in the functioning of key bodies.
'While we must uphold the highest standards of quality and safety, we must also avoid unnecessary delays, red tape must not become a barrier to timely progress,' the Union Minister said.
India's rise as a hub for pharmaceuticals and medical devices was spotlighted, with the Minister citing India's ability to meet global demand especially during the COVID-19 pandemic as evidence of its growing stature.
'We moved from being dependent to becoming the dependable,' he said.
Nadda reiterated the government's commitment to a citizen-first approach, built on innovation, collaboration and compassion. He called on the industry and all stakeholders to contribute to making India a global benchmark in healthcare by 2047. (ANI)
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
4 hours ago
- Mint
India's booming beauty industry has a serious problem of quality. New rules target this menace
New Delhi: India has tightened rules to ensure stricter testing and labelling of cosmetics to enhance safety, check counterfeit products and clearly define spurious items, said two officials aware of the development. A failure to comply with the new rules introduced by the health and family welfare ministry will result in the suspension and cancellation of licences, according to the officials cited earlier and documents reviewed by Mint. The Cosmetics (Amendment) Rules, 2025 were finalized and notified on 29 July after a detailed consultative process with the relevant stakeholders and further consultation with the Drugs Technical Advisory Board, a top drug advisory panel, said the first official quoted earlier. The changes include setting up a dedicated Central Cosmetics Laboratory to test products before they hit the shelves. India's cosmetics market—including skin, hair and oral care, fragrances, and colour products—is estimated at $20 billion, growing at an annualized rate of 25%, according to India Brand Equity Foundation. New brands have been mushrooming as rising incomes spur consumption. However, that also brought a myriad of new products claiming to provide unverified benefits, especially when peddled by celebrities and influencers. Stricter rules aim to curb exaggerated claims and ensure higher standards that will also benefit exports. "The cosmetic industry in India is largely under-regulated, particularly concerning product claims. Unlike in many other countries, companies here can make unsubstantiated assertions—such as promising to make a person several shades fairer or claiming to stop hair fall—that are often misleading,' said Dr Dinesh Kumar Devaraj, president, Indian Association of Dermatologists, Venereologists & Leprologists (IADVL), Tamil Nadu. 'This is where regulatory checks are critically needed.' Queries sent to the health ministry spokesperson and cosmetic manufacturers, including Hindustan Unilever Ltd, on Friday remained unanswered. Cosmetics in India are regulated under the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The Central Drugs Standard Control Organization (CDSCO) is the main regulatory body responsible for implementing the rules. 'Lots of clerical and administrative corrections have been made in cosmetics rules,' the first official quoted earlier said. 'These comprehensive measures signal a serious commitment by the government to prioritize consumer safety and bring greater transparency to India's cosmetics industry.' Manufacturers will now have to keep detailed records of all raw materials and manufactured batches for three years or six months after the batch expires, whichever is later. This improved record-keeping will significantly enhance the traceability of products in case of a safety concern. The new regulations require that labels on cosmetics to be exported meet the legal standards of the destination country. A cornerstone of the new policy is the Central Cosmetics Laboratory to test samples. It will also be an appellate laboratory, ensuring a centralized and rigorous approach to product quality. The rules, for the first time, empower the State Licensing Authority to suspend or cancel a license if a company fails to comply with any of its conditions or with any provision of the Act or the rules. This order will be issued in writing after giving the licencee an opportunity to show cause and be heard. However, a manufacturer whose licence is suspended or cancelled has the right to appeal the decision to the state government within 90 days, ensuring due process is followed. The new regulations specifically define 'spurious cosmetics' under section 17D of the Act, strengthening the government's ability to crack down on counterfeit items. That provides a stronger legal basis for regulatory bodies to crack down on such items. The rules also seek to streamline international trade. 'The cosmetic is meant for export, then the label on the package or container of cosmetic shall comply with the law of the country to which the cosmetic is to be exported,' the notification said. Similarly, a specific provision has been added to allow for a code number instead of the manufacturer's name and address on the label if the importer requires it. These changes are designed to protect consumers from unsafe and counterfeit cosmetic products while strengthening the regulatory framework, the second official quoted earlier said. According to the L'Oréal India spokesperson, the updated cosmetic regulations enhance clarity and compliance, '…particularly the provision for export labelling, which significantly streamlines international trade, benefiting our exports from India to 25 countries'. Citing that 95% of its products sold in India are locally manufactured, the spokesperson said these 'progressive changes further support our 'Make in India' endeavors and our mission to provide high-quality beauty solutions both domestically and internationally'. The industry has also come under scrutiny after complaints regarding mercury-based products, Mint reported earlier. Products such as skin-lightening creams, 'anti-ageing solutions' for freckles and dark spots and certain makeup items are known to contain the toxic element. Dr. Devaraj said another concern is the misuse of steroids in cosmetics for skin brightening, which can lead to significant dermatological damage. 'As a doctor, I can easily distinguish between skin that has been brightened by such steroid use and skin that is healthy,' he said. 'The issue of wrong or non-existent labelling also needs to be addressed. Furthermore, there is a complete lack of regulation on pricing, which allows for a dramatic disparity in costs for similar products.' The validation provided by celebrities and social media influencers heavily influences consumers, especially first-time buyers, according to him. 'Given our vast population, a small fraction of buyers can generate significant profit for a company, reducing the need for repeat business,' said Dr. Devaraj. 'This trend has been amplified by the rise in online sales and paid promotions post-Covid.'
Mint
5 hours ago
- Mint
NEET PG 2025 exam: From answer keys and result date to website and more - Here's all you need to know
NEET PG 2025: The National Board of Examinations in Medical Sciences (NBEMS) conducted the NEET PG 2025 exam on Sunday, and over 2.42 lakh students appeared for admission to various postgraduate medical courses. The NBEMS conducted the NEET PG 2025 exam on a computer-based platform in a single shift across 301 cities and 1052 test centres. For the NEET PG 2025 exam, the NBEMS engaged over 2,200 faculty members from various medical colleges and accredited hospitals, ensuring zero tolerance towards use of unfair means cases. Also, to prevent any kind of cyber scam at test centres, NBEMS took assistance from the Indian Cybercrime Coordination Centre (I4C), Ministry of Home Affairs. Even aound 300 cyber commandos fanned out to various exam centres, especially the sensitive ones, to prevent any kind of cheating at these test centres, officials said. The NEET PG 2025 exam was conducted on 3 August and it began at 9 AM. The exams conclude at 12.30 pm. NBEMS will not release the NEET PG 2025 question paper, citing the nondisclosure agreement. However, the unofficial question paper based on the memory of exam-taking students will be released. The NBEMS will announce the NEET PG 2025 result on 3 September, and upload the result PDF, comprising qualified candidates on the official website, The NBEMS will not send NEET PG 2025 result on email. According to students, questions were asked from Gynae, Pharmacology, Opthalmology, Surgury etc. As per the details, the total mark for NEET PG 2025 exam is 800. The NBEMS will award 4 marks for right answer and deduct one mark for the wrong answer.
Economic Times
8 hours ago
- Economic Times
Cancer cure? Russia commences human trials of revolutionary personalized cancer vaccine
In a landmark advancement for oncology and personalized medicine, Russia's Gamaleya National Research Center of Epidemiology and Microbiology—the creators of the Sputnik V COVID-19 vaccine—announced this year that it will begin human clinical trials of the world's first personalized mRNA-based melanoma vaccine within the next few months. Alexander Gintsburg, director of the Gamaleya Center, confirmed that this groundbreaking vaccine, tailored specifically to the genetic profile of individual patients' tumors, will start experimental administration as early as September-October 2025 in collaboration with leading Russian oncology institutions. Q. What are melanoma cellsA. Melanoma cells come from melanocytes, the skin cells that give it color. When these cells grow too much and become cancerous, they cause melanoma, a dangerous kind of skin cancer that can spread fast if not treated early. Q. What is mRNA, and how is it used in vaccines? A. mRNA, or messenger RNA, is a molecule that carries genetic instructions from DNA to the cell's protein-making machinery. It acts like a messenger, conveying the code needed to build specific proteins that perform various functions in the body. In vaccines, mRNA teaches cells to produce a harmless piece of a virus or cancer antigen, triggering the immune system to respond and protect the body. This novel cancer vaccine is designed to train the immune system to recognize and attack melanoma cells by creating a bespoke mRNA blueprint derived from each patient's unique tumor mutations. The process involves sophisticated artificial intelligence algorithms that analyze the tumor's genetic data to produce a molecular template, which is then synthesized at Gamaleya's production facilities. This tailor-made mRNA encodes proteins that activate a targeted cytotoxic immune response, aiming not only to eradicate primary tumors but also to address metastatic cancer elaborated that the entire vaccine development cycle—from tumor sequencing to vaccine production—can be completed within about one week due to AI-assisted mathematical modeling and neural network computing. This rapid manufacture represents a significant leap compared to typical timelines in personalized cancer therapies. Q. What is a personalized cancer vaccine?A. Personalized cancer vaccine is a tailored immunotherapy designed to train the patient's immune system to recognize and attack their specific cancer cells. It uses information from the patient's tumor genetics to create a unique vaccine that targets tumor-specific mutations, differing from general vaccine model was developed starting in mid-2022 and has already demonstrated promising efficacy in preclinical animal studies, showing the ability to suppress tumor growth and reduce metastasis. The upcoming Phase I clinical trials will take place at two of Russia's foremost oncology centers: the Hertsen Research Institute and the N.N. Blokhin National Medical Research Center of Oncology in Moscow. Importantly, this tailored vaccine is part of a wider Russian initiative to advance cancer treatment across various difficult-to-treat types, including pancreatic, kidney, and non-small-cell lung cancers. The Russian Ministry of Health classifies this vaccine development and approval under a new, specialized regulatory process recognizing its individualized nature, differing fundamentally from traditional drug registration. The state plans to provide this cancer vaccine free of charge to Russian citizens, with an estimated production cost of around 300,000 rubles (approx. USD 2,869) per dose covered by government to health authorities, about 4 million Russians live with cancer, and approximately 625,000 new cancer cases are diagnosed annually, underlining the urgent need for innovative therapies. The vaccine's success could mark a pivotal moment in Russia's fight against cancer and elevate its personalized medicine the COVID-19 mRNA vaccines designed to target a single viral antigen, this personalized cancer vaccine encodes multiple neoantigens specific to each patient's tumor, offering a multi-targeted immune approach.
